Cardiol Therapeutics (CRDL) Change in Account Payables (2020 - 2026)

Cardiol Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Change in Account Payables rose 138.73% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $916876.1 (up 205.04% YoY) and the FY2025 annual result came in at $189087.8, up 124.81% from the prior year.
• Change in Account Payables was $1.2 million for Q1 2026 at Cardiol Therapeutics, up from -$2.5 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $2.0 million in Q3 2025 and bottomed at -$2.5 million in Q4 2025.
• A 5-year average of $183612.9 and a median of $488094.6 in 2024 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables surged 1125.24% — and 2024, when it sank 13493.07%.
• Cardiol Therapeutics' Change in Account Payables stood at $1.2 million in 2022, then sank by 49.56% to $624557.2 in 2023, then fell by 21.85% to $488094.6 in 2024, then plunged by 613.9% to -$2.5 million in 2025, then soared by 149.06% to $1.2 million in 2026.
• Business Quant data shows CRDL's Change in Account Payables at $1.2 million in Q1 2026, -$2.5 million in Q4 2025, and $2.0 million in Q3 2025.